Nancy Olivieri | Academic Influence

Q: What Schools Are Affiliated With Nancy Olivieri

Nancy Olivieri is affiliated with the following schools: McMaster University, Cornell University, University of Toronto

Why Is Nancy Olivieri Influential?

According to Wikipedia, Nancy Fern Olivieri is a prominent Toronto haematologist and researcher with an interest in the treatment of haemoglobinopathies. She is best known for a protracted struggle with the Hospital for Sick Children and the pharmaceutical company Apotex about the drug deferiprone.

(See a Problem?)

Nancy Olivieri's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Iron-chelating therapy and the treatment of thalassemia. (1997) (1078)
Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. (2003) (864)
Survival in Medically Treated Patients with Homozygous β-Thalassemia (1994) (781)
A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. (2006) (658)
The β-Thalassemias (1999) (582)
A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders. (1993) (462)
Survival in medically treated patients with homozygous beta-thalassemia. (1994) (434)
Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. (1998) (373)
The beta-thalassemias. (1999) (361)
Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. (1995) (353)
Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. (1986) (347)
Prospective RBC phenotype matching in a stroke‐prevention trial in sickle cell anemia: a multicenter transfusion trial (2001) (304)
Iron-chelation therapy with oral deferiprone in patients with thalassemia major. (1995) (303)
Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial (2003) (299)
Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. (1985) (261)
Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study (2007) (256)
Stroke prevention trial in sickle cell anemia. (1998) (256)
Bone Disease in Thalassemia: A Frequent and Still Unresolved Problem (2008) (213)
Experimental verocytotoxemia in rabbits (1992) (172)
Barriers to bone marrow transplantation for sickle cell anemia. (1996) (171)
Results of long‐term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators (1995) (166)
Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients (1990) (160)
Extended therapy with intravenous arginine butyrate in patients with beta-hemoglobinopathies. (1995) (159)
Secondary iron overload. (2001) (156)
Effect of age at the start of iron chelation therapy on gonadal function in beta-thalassemia major. (1990) (153)
Differences in the prevalence of growth, endocrine and vitamin D abnormalities among the various thalassaemia syndromes in North America (2009) (151)
Thalassaemia in Sri Lanka: implications for the future health burden of Asian populations (2000) (147)
Morbidity and mortality in chronically transfused subjects with thalassemia and sickle cell disease: A report from the multi‐center study of iron overload (2007) (147)
Inherited Disorders of Hemoglobin (2006) (139)
Growth failure and bony changes induced by deferoxamine. (1992) (132)
Changes in the Epidemiology of Thalassemia in North America: A New Minority Disease (2005) (126)
Uptake of non-transferrin-bound iron by both reductive and nonreductive processes is modulated by intracellular iron. (1994) (122)
Molecular analysis of the high-hemoglobin-F phenotype in Saudi Arabian sickle cell anemia. (1987) (118)
Iron overload cardiomyopathies: New insights into an old disease (1994) (118)
Progression of iron overload in sickle cell disease. (2001) (117)
Critical Comparison of Novel and Existing Methods of Compliance Assessment During a Clinical Trial of an Oral Iron Chelator (1994) (108)
Hb E/beta-thalassaemia: a common & clinically diverse disorder (2011) (107)
Studies in haemoglobin E beta‐thalassaemia (2008) (106)
Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassemic and sickle red blood cells both in vitro and in vivo. (1995) (102)
Pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine infusions. (1990) (102)
Stroke risk in siblings with sickle cell anemia. (2003) (102)
Infection due to Yersinia enterocolitica in a series of patients with beta-thalassemia: incidence and predisposing factors. (1998) (98)
Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injury. (2009) (96)
The therapeutic reactivation of fetal haemoglobin. (1998) (95)
Engraftment of immune-deficient mice with primitive hematopoietic cells from beta-thalassemia and sickle cell anemia patients: implications for evaluating human gene therapy protocols. (1995) (91)
Prevalence of fractures among the Thalassemia syndromes in North America. (2006) (87)
Inflammation and oxidant-stress in β-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial (2008) (84)
Compliance assessed by the Medication Event Monitoring System. (1991) (82)
Iron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell disease. (1994) (81)
Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia (1992) (80)
IDENTIFICATION OF MICRODELETIONS SPANNING THE DIAMOND-BLACKFAN ANEMIA (DBA) LOCUS ON 19Q13 AND EVIDENCE FOR GENETIC HETEROGENEITY (1998) (79)
Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia. (1992) (79)
Hydroxyurea in Children with Sickle Cell Disease: Impact on Splenic Function and Compliance with Therapy (1998) (78)
Diamond-Blackfan anemia: heterogenous response of hematopoietic progenitor cells in vitro to the protein product of the steel locus. (1991) (76)
Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort. (2012) (74)
Effects of iron loading on uptake, speciation, and chelation of iron in cultured myocardial cells. (1993) (71)
Analgesia in children with sickle cell crisis: comparison of intermittent opioids vs. continuous intravenous infusion of morphine and placebo-controlled study of oxygen inhalation. (1992) (71)
Effect of long-term transfusion on growth in children with sickle cell anemia: results of the STOP trial. (2005) (71)
Visual and Auditory Neurotoxicity in Patients Receiving Subcutaneous Deferoxamine Infusions (1986) (69)
Iron chelation adherence to deferoxamine and deferasirox in thalassemia (2011) (66)
A pilot study of subcutaneous decitabine in β-thalassemia intermedia. (2011) (66)
Risk factors and mortality associated with an elevated tricuspid regurgitant jet velocity measured by Doppler-echocardiography in thalassemia: a Thalassemia Clinical Research Network report. (2011) (66)
Iron Deposition in the Anterior Pituitary in Homozygous Beta-Thalassemia: MRI Evaluation and Correlation with Gonadal Function (2000) (65)
Treatment of thalassaemia major with phenylbutyrate and hydroxyurea (1997) (64)
Butyrate derivatives. New agents for stimulating fetal globin production in the beta-globin disorders. (1994) (62)
Brief report: combined liver and heart transplantation for end-stage iron-induced organ failure in an adult with homozygous beta-thalassemia. (1994) (61)
Trying to improve compliance with prophylactic penicillin therapy in children with sickle cell disease. (1998) (60)
Two novel beta-thalassemia mutations in the 5' and 3' noncoding regions of the beta-globin gene. (1992) (60)
βs Haplotypes in various world populations (1992) (60)
Haemoglobin E β thalassaemia in Sri Lanka (2005) (60)
Trial of recombinant human erythropoietin: three patients with thalassemia intermedia [letter] (1992) (59)
Patients’ health or company profits? The commercialisation of academic research (2003) (58)
Modulation by iron loading and chelation of the uptake of non-transferrin-bound iron by human liver cells. (1995) (58)
Hepcidin is suppressed by erythropoiesis in hemoglobin E β-thalassemia and β-thalassemia trait. (2015) (56)
Long-term therapy with deferiprone. (1996) (56)
Safety and efficacy of pegylated interferon α-2a and ribavirin for the treatment of hepatitis C in patients with thalassemia (2008) (55)
Fetal haemoglobin augmentation in E/β0 thalassaemia: clinical and haematological outcome (2005) (54)
Interaction of malaria with a common form of severe thalassemia in an Asian population (2009) (53)
The effects of subcutaneous deferoxamine administration on renal function in thalassemia major. (1991) (52)
Age-related changes in adaptation to severe anemia in childhood in developing countries (2007) (52)
Genetic determinants of jaundice and gallstones in haemoglobin E β thalassaemia (2001) (50)
Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone (2013) (50)
Quantification of cardiac and tissue iron by nuclear magnetic resonance relaxometry in a novel murine thalassemia-cardiac iron overload model. (1996) (49)
Arthropathy in thalassaemia patients receiving deferiprone (1994) (48)
Haemoglobin E beta thalassaemia in Sri Lanka. (2005) (47)
Characterization of Fe2+ and Fe3+ transport by iron-loaded cardiac myocytes. (1997) (45)
Reactivation of fetal hemoglobin in patients with beta-thalassemia. (1996) (44)
Influence of steel factor on hemoglobin synthesis in sickle cell disease. (1992) (40)
Sildenafil therapy in thalassemia patients with Doppler-defined risk of pulmonary hypertension (2013) (39)
A novel molecular basis for beta thalassemia intermedia poses new questions about its pathophysiology. (2005) (39)
Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility (2003) (39)
HbE/β-thalassemia: basis of marked clinical diversity. (2010) (38)
Relationship between chronic transfusion therapy and body composition in subjects with thalassemia. (2010) (37)
An alpha-globin gene initiation codon mutation in a black family with HbH disease. (1987) (36)
Speciation of tissue and cellular iron with on-line detection by inductively coupled plasma-mass spectrometry. (1992) (36)
Mutations in the erythropoietin receptor gene are not a common cause of Diamond-Blackfan anemia. (1996) (35)
Beta S haplotypes in various world populations. (1992) (35)
Genetic determinants of jaundice and gallstones in haemoglobin E beta thalassaemia. (2001) (35)
Beliefs about chelation among thalassemia patients (2012) (34)
Adaptation to anemia in hemoglobin E-ß thalassemia. (2010) (33)
Trial of recombinant human erythropoietin: three patients with thalassemia intermedia. (1992) (33)
Comparison of deferoxamine pharmacokinetics between asymptomatic thalassemic children and those exhibiting severe neurotoxicity (1990) (31)
Pain Perception and Effectiveness of the Eutectic Mixture of Local Anesthetics in Children Undergoing Venipuncture (1992) (31)
Disparity in the management of iron overload between patients with sickle cell disease and thalassemia who received transfusions (2008) (31)
Identification of a novel termination codon mutation (TAA-->TAT, Term-- >Tyr) in the alpha 2 globin gene of a Laotian girl with hemoglobin H disease [letter] (1994) (30)
5 Thalassaemia: clinical management (1998) (29)
A Phase II Study with ICL670 (Exjade®), a Once-Daily Oral Iron Chelator, in Patients with Various Transfusion-Dependent Anemias and Iron Overload. (2004) (29)
Assessment of the effect of the oral iron chelator deferiprone on asymptomatic Plasmodium falciparum parasitemia in humans. (1998) (29)
Thalassemia in Sri Lanka: a progress report. (2004) (28)
Hemoglobin H (Hb H) disease in Canada: Molecular diagnosis and review of 116 cases (2001) (27)
Diurnal variation in the pharmacokinetics and myelotoxicity of mercaptopurine in children with acute lymphocytic leukemia. (1990) (27)
Rapid healing of chronic leg ulcers during arginine butyrate therapy in patients with sickle cell disease and thalassemia. (1994) (27)
Reduction in tissue iron stores with a new regimen of continuous ambulatory intravenous deferoxamine (1992) (26)
Failure of recombinant human interleukin-3 therapy to induce erythropoiesis in patients with refractory Diamond-Blackfan anemia. (1994) (26)
Hemoglobin H‐constant spring in North America: An alpha thalassemia with frequent complications (2009) (25)
The evolutionary and clinical implications of the uneven distribution of the frequency of the inherited haemoglobin variants over short geographical distances (2017) (25)
Studies of the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one in thalassemia patients. (1990) (24)
Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox (2019) (24)
Management of the thalassemias. (2013) (23)
Pregnancy outcomes in women with thalassemia in North America and the United Kingdom (2013) (23)
Iron overload and iron-chelating therapy in hemoglobin E-beta thalassemia. (2000) (23)
Dysregulated arginine metabolism and cardiopulmonary dysfunction in patients with thalassaemia (2015) (23)
Analysis of hemoglobin F production in Saudi Arabian families with sickle cell anemia. (1987) (23)
Identification of two novel β°‐thalassemia mutations in a filipino family: Frameshift codon 67 (− TG) and a β‐globin gene deletion (1993) (22)
Hb E/Hb LeporeHollandia in a family from Bangladesh (1994) (21)
Methemoglobinemia and ascorbate deficiency in hemoglobin E β thalassemia: metabolic and clinical implications. (2012) (21)
Expression of SCL is normal in transfusion-dependent Diamond-Blackfan anemia but other bHLH proteins are deficient. (1997) (21)
Mycobacterial brain abscess possibly due to bacille Calmette-Guérin in an immunocompromised child. (1992) (20)
Identification of a novel termination codon mutation (TAA-->TAT, Term-->Tyr) in the alpha 2 globin gene of a Laotian girl with hemoglobin H disease. (1994) (19)
Oral iron chelation with 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron loaded thalassemia patients. (1993) (19)
Valproic acid and augmentation of fetal hemoglobin in individuals with and without sickle cell disease. (1997) (19)
Hydroxycarbamide‐induced changes in E/beta thalassemia red blood cells (2008) (19)
Analysis of Hemoglobin F Production in Saudi Arabian Families With Sickle Cell Anemia (1987) (19)
Iron status and anaemia in Sri Lankan secondary school children: A cross-sectional survey (2017) (18)
Thalassaemia: clinical management. (1998) (18)
Cardiac Disease–free Survival in Patients with Thalassemia Major Treated with Subcutaneous Deferoxamine (1990) (18)
Treatment strategies for hemoglobin E beta-thalassemia. (2012) (17)
Long‐Term Trials of Deferiprone in Cooley's Anemia a (1998) (17)
Evaluation of the Oral Iron Chelator 1,2‐Dimethyl‐3‐hydroxypyrid‐4‐one (L1) in Iron‐Loaded Patients a (1990) (17)
Collaborative study of marrow transplantation for sickle cell disease: Aspects specific for transplantation of hemoglobin disorders (1997) (17)
Education and employment status of children and adults with thalassemia in North America (2010) (17)
A high-performance liquid chromatographic method for the measurement of the iron chelator 1,2-dimethyl-3-hydroxypyridin-4-one in human plasma. (1991) (16)
Unexpected complications after bone marrow transplantation in transfusion-dependent children. (1993) (15)
Novel mutation of the alpha 2-globin gene initiation codon (ATG-->A-G) in a Vietnamese girl with Hb H disease. (1997) (15)
Arthropathy in thalassaemia patients receiving deferiprone (1994) (15)
Alpha thalassaemia and extended alpha globin genes in Sri Lanka. (2013) (14)
Comparison of the pharmacokinetics of 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in healthy volunteers, with and without co-administration of ferrous sulfate, to thalassemia patients. (1993) (13)
Effects of deferoximine on chondrocyte alkaline phosphatase activity: Proxidant role of deferoximine in thalassemia (1995) (13)
Rarity of systemic lupus erythematosus after oral iron chelator L1 (1991) (13)
Diamond-Blackfan anemia: expansion of erythroid progenitors in vitro by IL-9, but exclusion of a significant pathogenetic role for the IL-9 gene and the hematopoietic gene cluster on chromosome 5q. (1997) (13)
The pharmacokinetics and pharmacodynamics of the oral iron chelator deferiprone (L1) in relation to hemoglobin levels. (1996) (12)
Deferiprone and hepatic fibrosis. (2003) (12)
Fetal erythropoiesis and the diagnosis and treatment of hemoglobin disorders in the fetus and child. (1997) (12)
Increase in Hemoglobin Concentration during Therapy with Hydroxyurea in Cooley's Anemia (1998) (11)
Computed tomography scanning of the liver to determine efficacy of iron chelation therapy in thalassemia major. (1989) (11)
Severity of β‐thalassemia due to genotypes involving the IVS‐I‐6 (T→C) mutation (1995) (10)
Urinary iron excretion depends on the mode of administration of the oral iron chelator 1,2‐dimethyl‐3‐hydroxypyrid‐4‐one in patients with homozygous β‐thalassemia (1994) (10)
Hemoglobin E-beta-thalassemia: Progress report from the International Study Group. (2005) (9)
Adherence to deferoxamine therapy: Heeding Hippocrates and Osler (2004) (9)
Induction of fetal hemoglobin in the presence of increased 3-hydroxybutyric acid associated with beta-ketothiolase deficiency. (1994) (9)
Detection of beta-thalassemia using an artificial-restriction fragment length polymorphism generated by the polymerase chain reaction. (1991) (9)
Saudi Arabian Sickle Cell Anemia a (1989) (8)
Disorders of Hemoglobin: Clinical Aspects of β Thalassemia and Related Disorders (2009) (8)
Laboratory parameters in patients randomized in the stop study and their modification by transfusion (2000) (7)
IDENTIFICATION OF TWO NEW α-THALASSEMIA MUTATIONS IN EXON 2 OF THE α1-GLOBIN GENE (2001) (7)
A new frameshift β°‐thalassemia mutation (codons 27–28 +C) found in a Chinese family (1991) (7)
Adaptation to anemia in hemoglobin E-β thalassemia (Blood (2010) 116, 24 (5368-5370)) (2011) (7)
Counseling sexually active teenagers treated with potential human teratogens. (1997) (7)
Discrepancies in self-reported financial conflicts of interest disclosures by physicians: a systematic review (2021) (7)
Chelation Choices and Iron Burden Among Patients with Thalassemia in the 21st Century: a Report From the Thalassemia Clinical Research Network (TCRN) Longitudinal Cohort. (2009) (6)
Increased leucocyte apoptosis in transfused β‐thalassaemia patients (2013) (6)
Identification of two novel beta zero-thalassemia mutations in a Filipino family: frameshift codon 67 (-TG) and a beta-globin gene deletion. (1993) (6)
Pulmonary Hypertension in Thalassemia Assessed by Echocardiography: A Report From Baseline Data of the Thalassemia Clinical Research Network Longitudinal Cohort Study. (2009) (6)
Biomedical conflicts of interest : a defence of the sequestration thesis — learning from the cases of (2004) (6)
Compound heterozygosity for two genotypes of alpha-thalassemia-2: hematological, biosynthetic and DNA studies. (1985) (6)
Use of a Eutectic Mixture of Local Anesthetics for Prolonged Subcutaneous Drug Administration (1995) (5)
Hemoglobin E/β Thalassemia: The Canadian Experience (1998) (5)
Genetic influences on bone disease in thalassemia. (1998) (5)
Analysis of high fetal hemoglobin production in sickle cell anemia patients from the Eastern Province of Saudi Arabia. (1987) (5)
Globin gene expression in Hb Lepore‐BAC transgenic mice (2006) (5)
Deferiprone-Induced Agranulocytosis (1997) (5)
Relative efficacy of subcutaneous infusions and bolus injections of deferoxamine in the removal of non-transferrin-bound iron (NTBI). (1998) (5)
Sildenafil Therapy in Patients with Thalassemia and an Elevated Tricuspid Regurgitant Jet Velocity (TRV) On Doppler Echocardiography At Risk for Pulmonary Hypertension: Report From the Thalassemia Clinical Research Network (2012) (5)
Methodological issues in studying the effect of the new oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) on absorption of iron. (1990) (5)
Improving Laboratory and Clinical Hematology Services in Resource Limited Settings. (2016) (5)
Headache: an important symptom possibly linked to white matter lesions in thalassaemia (2019) (5)
Survival and complications in patients with haemoglobin E thalassaemia in Sri Lanka: a prospective, longitudinal cohort study (2021) (4)
HSC clinical trials controversy continues (1999) (4)
Studies of iron excretion and non-transferrin-bound plasma iron (NTBP1), following a single infusion of hydroxyethyl starch-deferoxamine (HES-DFO): A new approach to iron chelation therapy. (1996) (4)
Interferon-γ Modulates Fetal Hemoglobin Synthesis in Sickle Cell Anemia and Thalassemia (1990) (4)
Diagnosis and management of thalassaemia. (2001) (4)
I beg to differ. (2002) (4)
Progression of Avascular Necrosis of the Hip in Sickle Cell Disease: 2 Year Follow-Up of Randomized Trial of Aggressive Physical Therapy and Hip Coring Decompression. (2004) (3)
Erratum: Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography (New England Journal of Medicine (1998) 339 (5-11)) (1998) (3)
Oxidative status in the β-thalassemia syndromes in Sri Lanka; a cross-sectional survey. (2021) (3)
Early Hepatitis C Viral Response (EVR) to Peginterferon Alfa 2a and Ribavirin in Patients with β Thalassemia. (2004) (3)
The β and δβ Thalassaemias in Association with Structural Haemoglobin Variants (2008) (3)
Adaptation to anemia in hemoglobin E-beta thalassemia (vol 116, pg 5368, 2011) (2011) (3)
Red Blood Cell Allo and Autoantibody Production in Patients in the Thalassemia Clinical Research Network. (2005) (3)
Safety and Efficacy of Peginterferon Alfa-2a and Ribavirin for Hepatitis C in Thalassemia. (2006) (3)
Transfusional Iron Overload (2002) (3)
Hemoglobin E/beta thalassemia: the Canadian experience. (1998) (3)
A “One-Stop” Screening Protocol for Haemoglobinopathy Traits and Iron Deficiency in Sri Lanka (2019) (3)
A Study on Children’s Condition Thalassemia Using Neutron Activation Analysis and Other Techniques (1994) (2)
Control of Oxidant-Stress and Inflammation by Iron Chelators Deferasirox (ICL670) or Deferoxamine in β-Thalassemia: An Ancillary Study of the Novartis CICL670A0107 Trial. (2005) (2)
Identification of two new alpha-thalassemia mutations in exon 2 of the alpha1-globin gene. (2001) (2)
Stroke prevention in sickle cell disease (stop): Final results (2000) (2)
Compound heterozygosity for Hb S and Hb G-Copenhagen. (1999) (2)
Interferon-gamma modulates fetal hemoglobin synthesis in sickle cell anemia and thalassemia. (1990) (2)
Orally active iron chelators in the treatment of iron overload (1996) (2)
Phenomenon of Pain In Thalassemia: A Prospective Analysis by the Thalassemia Clinical Research Network (TCRN) (2010) (2)
Cardiopulmonary and Laboratory Profiling of Patients with Thalassemia At Risk for Pulmonary Hypertension: Report From the Thalassemia Clinical Research Network. (2012) (2)
Consequences to patients, clinicians, and manufacturers when very serious adverse drug reactions are identified (1997–2019): A qualitative analysis from the Southern Network on Adverse Reactions (SONAR) (2020) (2)
A response from Dr. Nancy Olivieri (2006) (2)
The β Thalassaemias (2008) (2)
Biotin-Labeled RBC Survival in Thalassemia and Impact of Treatment. (2004) (2)
Leg Ulcers: A Report in Patients with Hemoglobin E Beta Thalassemia and Review of the Literature in Severe Beta Thalassemia (2021) (1)
Academic freedom, scientific integrity, and conflicts of interest: Lessons learned from the University of Toronto (2008) (1)
Hereditary Persistence of Fetal Haemoglobin (2008) (1)
Anemia But Other bHLH Proteins Are Deficient Expression of SCL Is Normal in Transfusion-Dependent Diamond-Blackfan (1997) (1)
Severity of beta-thalassemia due to genotypes involving the IVS-I-6 (T-->C) mutation. (1995) (1)
THE EFFECT OF NIGHTLY SUBCUTANEOUS DESFERAL ON GROWTH AND SEXUAL MATURATION IN CHILDREN WITH THALASSEMIA MAJOR (1984) (1)
The α Thalassaemias and Their Interactions with Structural Haemoglobin Variants (2008) (1)
CT SCANNING OF LIVER IRON DENSITY IN THALASSEMIA MAJOR: VALUABLE PREDICTOR OF CARDIAC DYSFUNCTION (1984) (1)
α Thalassaemia with Mental Retardation or Myelodysplasia (2008) (1)
Impact of a low transfusion regimen on growth and iron loading in haemoglobin E/beta thalassaemia (1999) (1)
Left Ventricular Function Declines with Increasing Myocardial Ferritin Iron in Thalassemia Major. (2005) (1)
Leukocyte Apoptosis and Mitochondrial Dysfunction in β-Thalassemia Patients Treated with Deferasirox or Deferoxamine. (2007) (1)
Body Composition and Its Relationship to Growth and Bone Mass in Patients with Thalassemia (2008) (1)
A Pilot Study of Epigenetic-Differentiation Therapy with Decitabine to Treat β-Thalassemia Intermedia (2010) (1)
Consequences to Patients, Clinicians, and Manufacturers When Very Serious Adverse Drug Reactions Are Identified (1997-2019): A Qualitative Analysis from the Southern Network on Adverse Reactions (SONAR). (2022) (0)
Pharmacokinetics of arginine butyrate in patients with hemoglobinopathy. (1996) (0)
The pharmacokinetics and pharmacodynamics of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one , depend on hemoglobin levels (1994) (0)
WASHED RED CELLS : STANDARD TRANSFUSION ? AUTHORS' REPLY (1995) (0)
The prognosis for adults with thalassemia major treated medical therapy: An interim report: Cagliari 1995 (1997) (0)
Hemoglobin H-Constant Spring in North America: A Common Alpha Thalassemia with Frequent Complications. (2008) (0)
Iron Overload and Iron-Chelating Therapy in Hemoglobin E-&bgr; Thalassemia (2000) (0)
SUBOPTIMAL MANAGEMENT OF PAIN CRISES IN SICKLE CELL DISEASE: PROSPECTIVE OBSERVATIONS (1990) (0)
The VIGOR and CLASS Trials: Cox-2 Inhibitors in the Dock The Celebrex scandal involved a drug trial with sixteen authors, eight of them employees of the drug company Pharmacia [later purchased by Pfizer, (2009) (0)
The Role of Deferiprone in Iron Chelation. (2019) (0)
Cardiac functions in older patients with haemoglobin E- β thalassaemia (2007) (0)
CHELATION THERAPY IN OLDER PATIENTS WITH THALASSEMIA MAJOR (1984) (0)
DNA diagnosis of Hb S and Hb Caribbean (α2β291 Leu→Arg) in a Jamaican family (1994) (0)
A response from (2006) (0)
Rates of Non-Transfusional Iron Accumulation (NTIA) In Hemoglobin E Thalassemia (2010) (0)
Haemoglobin Ethalassaemia in Sri Lanka (2005) (0)
Reappraisal of Symptoms and Signs of Uncomplicated Beta Thalassemia Trait. (2004) (0)
More on: optimal dose for stroke thrombolysis in Asians (2012) (0)
A new frameshift beta zero-thalassemia mutation (codons 27-28 +C) found in a Chinese family. (1991) (0)
#666 Two previously uncharacterized double heterozygous states for hemoglobin E (1998) (0)
Identification of Two Novel P"-Thalassemia Mutations in a Filipino Family: Frameshift (1993) (0)
Welfare of patients and clinicians: academic freedom is vital (2017) (0)
Techniques for primary screening for haemoglobinpathies in Sri Lanka: a comparison of single tube osmotic fragility (STOP) and dye test {DCIP) vs full blood count (FBC) (2007) (0)
Secondary hemochromatosis in Bthalassemia and sickle cell disease (2002) (0)
COMPOUND HETEROZYGOSITY FOR TWO GENOTYPES OF a-THALASSEMIA-2: HEMATOLOGICAL, BIOSYNTHETIC (1985) (0)
Vertebral Abnormalities by Spine Morphometry in Thalassemia. (2006) (0)
Cohort thalassemia patients: a report from the Thalassemia Longitudinal Chelation use and iron burden in North American and British (2012) (0)
AN INITIATION CODON MUTATION IN THE α1 GLOBIN GENE OF A BLACK FAMILY WITH HbH DISEASE (1987) (0)
DNA diagnosis of Hb S and Hb Caribbean (alpha 2 beta 2 91 Leu-->Arg) in a Jamaican family. (1994) (0)
Continuous intravenous infusion of morphine for the treatment of severe vaso-occlusive painful crises in children with sickle cell anemia (1991) (0)
thalassemia: metabolic and clinical implications β Methemoglobinemia and ascorbate deficiency in hemoglobin E (2012) (0)
Assessment Of Non-Transfusional Iron Accumulation In Asian Patients With Hemoglobin E β Thalassemia (2013) (0)
15th Scientific Congress of the European Society for Pediatric Hematology and Immunology (ESPHI) Bingen, Germany, 23–26 August 1995 (2005) (0)
Natural history of haemoglobin E/beta thalassaemia: the impact of splenectomy on growth and steady state hemoglobin levels (1999) (0)
High Prevalence of Fractures and Bone Pain in Thalassemia: The Thalassemia Clinical Research Network Experience. (2005) (0)
regions of the beta-globin gene (see comments) Two novel beta-thalassemia mutations in the 5' and 3' noncoding (2011) (0)
The δβ and Related Thalassaemias (2008) (0)
cause of Diamond-Blackfan anemia Mutations in the erythropoietin receptor gene are not a common (2011) (0)
Renal Dysfunction in Thalassemia. (2009) (0)
A study on children's condition thalassemia using neutron activation analysis and other techniques (2008) (0)
DIFFERENCES IN HEPCIDIN REGULATION DISTINGUISH MILD AND SEVERE PHENOTYPES OF E-BETA THALASSAEMIA (2013) (0)
Thalassaemia in Sri Lanka: A molecular basis. (1999) (0)
Effect of hydroxyurea treatment on erythropoiesis and RBC characteristics in E-beta thalassemia (2001) (0)
Event Monitoring System . Compliance assessed by the Medication (2007) (0)
Clinical studies on iron chelation in patients with thalassemia major. (1990) (0)
Reply (1995) (0)
Increased Nucleosomal DNA Fragmentation in Leukocytes of Thalassemia Patients. (2008) (0)
Low Bone Mass in Thalassemia: The Thalassemia Clinical Research Network (TCRN) Experience. (2004) (0)
Pregnancy in Thalassemia Patients and Their Partners in a Canadian Population. (2005) (0)
Risks Factors And Mortality Associated With Doppler-Defined-Pulmonary Hypertension In Thalassemia Major: A Report From The Thalassemia Clinical Research Network Longitudinal Cohort Study (2011) (0)

This paper list is powered by the following services:

Other Resources About Nancy Olivieri

en.wikipedia.org

What Schools Are Affiliated With Nancy Olivieri?

Nancy Olivieri is affiliated with the following schools: